Five Prime Therapeutics (FPRX) Posts Q4 Loss of 55c/Share

Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($0.55), $0.45 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $12.4 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Radnostix revenue falls 27% amid product recalls and FDA actions
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation